In another investigation, TFPI2 methylation in the feces of stage I to III CRC patients emerged as a potential biomarker for early CRC detection, demonstrating a sensitivity range of 76% to 89% and a specificity range of 79% to 93% [10, 79]. The gene discussed is TFPI2; the disease is colorectal carcinoma.